vosaroxin + cytarabine

Vosaroxin + cytarabine is a combination chemotherapy regimen investigated primarily for the treatment of relapsed or refractory acute myeloid leukemia (AML). Vosaroxin is a first-in-class anticancer quinolone derivative that intercalates DNA at GC-rich regions and inhibits topoisomerase II, leading to cell cycle arrest at G2/M and apoptosis. Unlike classic topoisomerase II inhibitors, vosaroxin does not generate free radicals or reactive oxygen species and exhibits p53-independent activity, potentially overcoming some forms of drug resistance. Cytarabine is an antimetabolite chemotherapeutic agent that incorporates into DNA during replication, causing direct DNA damage and inhibiting cell proliferation. Preclinical studies demonstrated synergistic or additive effects when combining these agents in AML models. Clinical trials have shown that this combination can improve complete response rates in patients with relapsed/refractory AML, particularly among older adults[1][3][5][6][7].

Brand names

None

Other names

None